Orion Group Annual Report 2012 and Corporate Governance Statement published
ORION CORPORATION STOCK EXCHANGE RELEASE 26 February 2013 AT 13.55 EET
The official financial statement documents, which include the financial statements, the report of the Board of Directors and the auditor's report are available in Finnish at http://www.orion.fi/Orion/Yhtiokokoukset/Yhtiokokous-2013/.
Orion's Corporate Governance Statement for year 2012, adopted by the Board of Directors, is published as a separate report in Finnish at http://www.orion.fi/en/Orion/Corporate-Governance/ and in English at http://www.orion.fi/en/Orion/Corporate-Governance/.
Olli Huotari Terhi Ormio
SVP, Corporate Functions VP, Communications
Orionintie 1A, FI-02200 Espoo
Orion is a globally operating Finnish company developing pharmaceuticals and diagnostic tests - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. Pharmaceutical R&D focuses on central nervous system drugs, oncology and critical care drugs, and Easyhaler® pulmonary drugs.
Orion's net sales in 2012 amounted to EUR 980 million and the company had about 3,500 employees. Orion's A and B shares are listed on NASDAQ OMX Helsinki.